I live in this field, as a computer scientist learning the biology, and trying to make a living with a bootstrapped company.
I wrote a post about why GATK - one of the most popular bioinformatic tools in Next Generation Sequencing should not be put into a clinical pipeline:
http://blog.goldenhelix.com/?p=1534
In terms of your ideal software strategy, I can speak to that as well, as I am actually attempting to do almost exactly what you suggesting. My team is all masters in CS & Stats, with focus on kick-ass CG visualization and UX.
We released a free genome browser (visualization of NGS data and public annotations) that reflects this:
http://www.goldenhelix.com/GenomeBrowse/
But you're right, selling software in this field is a very weird thing. It's almost B2B, but academics are not businesses and their alternative is always to throw more Post-Doc man-power at the problem or slog it out with open source tools (which many do).
That said, we've been building our business (in Montana) over the last 10 years through the GWAS era selling statistical software and are looking optimistically into the era of sequencing having a huge impact on health care.